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ABSTRACT 
USING A COST BENEFIT ANALYSIS TO SUPPORT THE DEVELOPMENT 
 OF A COMPREHENSIVE BUSINESS MODEL FOR A PRE-FILLED,  
PRE-LABELED, PRE-DILUTED, STERILELY PACKAGED,  
READY-TO-USE, SYRINGE-BASED ANESTHESIA 
 DELIVERY SYSTEM 
by Lance Brandon Kennedy 
December 2015  
The foundation of Certified Registered Nurse Anesthetists’ (CRNAs) entire 
profession is built on the ability to provide anesthetic services using a variety of 
medications in the safest, most efficient, cost-effective way possible.  The purpose of this 
capstone is to address, via a comprehensive cost benefit analysis, whether pre-filled 
syringe drug trays are a more cost-effective way to address problems as compared to vial-
filled drug trays and to implement the necessary transitions in order to improve outcomes.  
There are a number of identifiable problems related to anesthesia medication delivery via 
vial-filled medication, including increased cost of healthcare, decreased patient safety to 
provider inconvenience, increased medication errors, and increased contamination.  The 
method of medication delivery has gained the attention of significant governing bodies 
such as the Joint Commission of Healthcare Organizations (JCAHO), Centers for Disease 
Control (CDC), and American Association of Nurse Anesthetists (AANA), just to name a 
few.  The best methods for change were evaluated in order to facilitate the most optimal 
quality improvement.  According to the AANA, “the available information is sufficient to 
promote the implementation of pre-filled or premixed syringes in anesthesia departments  
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to reduce the number of adverse drug events (ADEs) and become compliant with the 
Joint Commission, and Institute of Medicine” (Brown, 2014, pp. 465-469).   
The future change in anesthesia drug delivery is undeniable, and the data provide 
clearly defined recommendations and guidelines supporting the use of pre-filed syringes.  
Providing medications in pre-filled syringes would reduce medication errors and 
treatment delays, improve patient safety, and effectively meet the expectations, 
recommendations, and guidelines of governing entities (Fahimi et al., 2008).  “When you 
look at the impact of the initiative on quality and safety for the patients, it’s [just] what’s 
right to do” (Blum, 2013, p. 3). 
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CHAPTER I 
INTRODUCTION 
Statement of the Problem 
Imagine, for a moment, a happy and mischievous four-year-old little boy, full of 
life and laughter.  His name is Jacobi Hill.  Imagine his big brown eyes lighting up as he 
lets out an infectious laugh. Imagine his contagious smile as he hid his mom’s car keys, 
as he often did (Burns, 2010).  Imagine a cool crisp morning as his parents take him for 
‘routine’ dental surgery.  Fast-forward to the OR and now imagine this dream turns into a 
nightmare.  Imagine his anesthesia provider struggling to ventilate the little boy after he 
has been rendered incapable of protecting his own airway.  The anesthesiologist’s left 
hand is firmly securing the mask to the little boys face, and his right hand is applying 
positive pressure to the bag attempting to break what is seemingly a laryngospasm, but he 
is still unable to ventilate.  Anyone in anesthesia knows that this little boy needs a life-
saving, short acting paralytic, like succinylcholine.  The problem is that at this point, it 
would require it to be “drawn up” from the vial and with both hands occupied, someone 
else, less familiar with the drugs and too inexperienced to prepare the drug quickly and 
safely, must attempt to do so when every second that passes is another second without 
oxygen.  The little boy is finally given the appropriate medication, intubated, and taken to 
intensive care unit where he remains for the next few days until he eventually dies.  This 
is so tragic, but the worst part is that it was potentially preventable.  Had there been a 
system in place that would allow immediate administration of life-saving  drugs without 
the risk of medication waste and medication errors, perhaps little Jacobi Hill still be alive. 
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Background and Significance 
The intent of this comprehensive cost benefit analysis is to provide the highest 
quality medical supplies to healthcare providers in order to improve the quality of 
healthcare.  Identifiable problems related to anesthesia medication delivery via vial-filled 
medication include: (1) Significant increased healthcare cost related to medication waste 
and dilutional drug errors (U.S. National library of Medicine National Institute of Health, 
2011); (2) Increased possibility of contamination and infection due to drawing up 
medication without the use of a sterility hood, while frequently under hurried conditions. 
Also, some medications have a very short time to expiration when drawn up by the 
provider, as opposed to under sterile pharmacy conditions (Fahimi et al., 2008); and (3) 
During an acute condition such as a laryngospasm, hypotension, or bradycardia, time to 
draw up emergency drugs takes away precious time from the patient, and can result in 
frightful negative outcomes (Adapa et al.,  2012). 
Additionally, governing entities such as the Joint Commission, CDC, and the 
AANA have recommendations and guidelines that support pre-filled syringes, and make 
it virtually impossible to practice without using them.  The 2010 National Patient Safety 
Goals state that “when a drug is drawn into a syringe or otherwise used from its original 
container it must be immediately administered.  ‘Immediate administration’ means with 
no intervening steps or functions prior to administration” (The 2010 National Patient 
Safety Goals, 2010, p. 5).  The CDC Infection Prevention Checklist for Outpatient 
Settings: Minimum Expectations for Safe Care states that “Injections [should be] 
prepared using aseptic technique in a clean area free from contamination or contact with 
blood, body fluids or contaminated equipment” (CDC, 2013, p. 6).  This means that 
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medication should be drawn and labeled outside of patient areas, including the operating 
room.  Furthermore, according to the AANA (2014), the use of pre-filled or premixed 
medication and electronic documentation have been shown to reduce the number of 
Adverse Drug Events (ADEs) by as much as 21%, and, according to the IOM, 
approximately $2 billion is spent annually on ADEs in hospital settings.  This would 
mean a $420,000,000 decrease in healthcare cost just on ADEs alone. Moreover, the Joint 
Commission standard MM.05.01.07 states that medication preparation should either be 
done by a pharmacist or under the direct supervision of a pharmacist.  The AANA 
concludes that the savings justifies the cost, and “the available information is sufficient to 
promote the implementation of pre-filled or premixed syringes in anesthesia departments 
to reduce the number of adverse drug events and become compliant with the Joint 
Commission, and Institute of Medicine” (Brown, 2014, pp. 465-469). 
Each of these problems has a significant cost attached to them.  If anesthesia 
providers would be willing to make an effort to move toward compliance with the 
governing bodies’ guidelines and recommendations, they would simultaneously promote 
safety, improve outcomes, and decrease the cost of healthcare.  The purpose of the 
capstone is to address, via a comprehensive cost benefit analysis, whether pre-filled 
syringe drug trays are a more cost-effective way to address these problems as compared 
to vial-filled drug trays and, if so, to find methods to implement necessary transitions.    
Concept Analysis 
 Anesthesia medication delivery affects the lives of every patient who ever needs 
to undergo surgery and require anesthetic services.  In constructing a concept analysis, 
the first step is selecting a concept, then determining the aim of the analysis, followed by 
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identifying uses for the concept, determining the defining attributes, identifying model 
cases, antecedents, and consequences, and finally, defining empirical referents (Butts & 
Rich, 2015).  Two models are used to evaluate the differences between vial-filled 
anesthesia drug trays and pre-filled syringe anesthesia drug trays.  The first quality 
improvement model utilized is the Plan-Do-Study-Act (PDSA) cycle (The Deming 
Institute, 2013).  PDSA is a four-tier problem-solving model used for quality 
improvement.  When applying the PDSA model it is important to consider what our goal 
is and to consider if the change is an improvement.  The goal is to develop a 
comprehensive business model for a pre-filled, pre-labeled, pre-diluted, sterilely 
packaged, ready-to-use syringe based anesthesia delivery system.  A cost benefit analysis 
will identify and validate the results of the syringe based anesthesia delivery system, and 
determine that it is indeed a substantial improvement. 
The PDSA model has two cycles. Cycle one involved the planning phase, 
including brainstorming and implementing the proposed changes to improve the 
anesthesia drug delivery to improve outcomes via pre-filled, pre-diluted, sterilely 
packaged, ready-to-use syringes in an anesthesia delivery system.  Next, commonly used 
drugs, their dilutions, and their organization and cost, were identified and compared 
against pre-filled syringes.   
The results were then analyzed, costs were compared, and evidence identified an 
obvious cost benefit in multiple areas including medication waste, medication errors, 
decreased time of anesthetic induction, and increased patient safety.  Further study is 
needed to identify more specifically how much dilutional errors cost on a national, 
regional, and local facility level, but, approximately $2 billion is spent annually on ADEs 
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in hospital settings, and the AANA cites the use of pre-filled syringes to decrease this by 
as much as 21% (Brown, 2014, pp. 465-469).  Therefore, healthcare costs stand to be 
decreased, at the very least $420,000,000 annually.  The final portion of this model 
involved initiating a business plan and the considering of standardization options.  Once 
cycle one is complete and results are analyzed, the PDSA cycle 2 can begin and an 
evaluation can be made to consider which areas were successful and which areas were 
not.  
The second model used to evaluate the difference between vial-filled medication 
trays and pre-filled medication trays pertains to transitions within professional practice.  
The transition process begins when life events create the need for change.  The 
management of these transitions has profound effects on life, well-being, and health.  The 
transitions model can be used to optimize the nursing profession and better prepare 
nurses to work efficiently in a diverse healthcare system (Young and Wilkerson, 2010).   
There are three phases in the concept of the Transitions Model according to 
Young and Wilkerson (2000).  Phase one is the ‘ending phase’, which is the release of 
familiar ways.  The ending phase requires the person in transition to recognize the need 
for change, and be willing to let go of the status quo to step outside of their comfort zone 
and be open to other possibilities.  The second phase is the ‘neutral phase’ and it involves 
ambiguity and disequilibrium.  Here, accustomed ideas are disrupted and lost, and the 
transitions require the use of personal, interpersonal, and various environmental means to 
assist the change process.   The third phase is the ‘reorientation phase’.  In this phase, 
feelings of synchronization and harmony are restored, creating new meaning and 
independence.  There is an acceptance of the new challenges and a sense of ownership in 
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the new situation.  Positive outcomes include restitution, encouragement, security, and 
preservation.   Change is difficult and often resisted, however, change is necessary in 
order to grow and improve outcomes (Young and Wilkerson, 2010).   
 The cost of healthcare is increasing due to preventable problems associated with the 
system and policy, or lack thereof, which hinders improved outcomes. One example 
would be when an anesthetized patient has an episode of bradycardia in response to the 
surgeon manipulating the vagus nerve.  In response to that bradycardia the anesthesia 
provider removes the top from the vial and draws up the atropine.  Then, as commonly 
happens, the surgeon stops manipulating the vagus nerve which causes the patient’s heart 
rate to return back to normal, omitting the need for administration of atropine. The 
anesthesia provider acted responsibly in response to the bradycardia. However, the fact 
remains that not only was that patient charged for a drug that they never actually 
received, but the drug is now wasted after the procedure, which increases the overall cost.   
 Another example involves a patient who suddenly has a fairly common 
complication called laryngospasm during extubation.  It is imperative that if the spasm 
cannot be broken with other methods, that paralytic be given in order to ventilate the 
patient, as in the example previously presented of little Jacobi Hill.  This is not the time 
to have to turn your back on a patient and take minutes to draw up succinylcholine while 
the patient is de-saturating because their anesthesia provider cannot hold positive 
pressure due to the fact that they are too busy drawing up medication.  It is clear to see 
how much safer it would be for a patient to be protected by a policy that could foresee 
issues and prevent ADEs ahead of time and standardized pre-filled syringes for 
immediate administration.  
   
 
7 
Review of Related Literature  
A systematic literature review was conducted to direct, design, and develop this 
capstone project using the Agency for Healthcare Research and Quality (AHRQ), the 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), Cochrane Library, 
Centers for Medicare and Medicaid Services (CMS), JCAHO, the CDC, the AANA, 
EBSCO, and other evidence based resources.    
The PICO question that guided this literature review and project was: In patients 
undergoing surgery, who require anesthesia, do vial-filled medication delivery systems 
potentiate a risk to patient safety, decrease outcomes, increase medication waste, and 
increase cost of healthcare?  A literature review was used to determine if measures were 
taken to have pre-filled syringes prepared in an anesthesia drug tray, would that result in 
a safer, more cost-effective practice with less medication errors, less drug delays, and 
faster turnover. 
In 2010, JCAHO released updated labeling criteria to be followed in procedural 
areas.  The 2010 National Patient Safety Goals state that “when a drug is drawn into a 
syringe or otherwise used from its original container it must be immediately 
administered.  ‘Immediate administration’ means with no intervening steps or functions 
prior to administration.  [They further outline labeling medications and solutions in the 
context of NPSG.03.04.01 which state that] the labeling expectation for this safety goal 
are consistent with the requirements which state that the label must include: The drug 
name, strength, and amount, expiration date when not used within 24 hours, expiration 
time if less than 24 hours (which applies to only a few drugs), as well as the date 
prepared and diluents for all compounded IV admixtures.  [In light of these safety goals, 
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the Joint Commission] approves the purchase and use of pre-filled, pre-labeled syringes 
such as on procedure trays.” (The 2010 National Patient Safety Goals, 2010, pp. 5-6) 
The CDC Infection Prevention Checklist for Outpatient Settings: Minimum 
Expectations for Safe Care states that “Injections are prepared using aseptic technique in 
a clean area free from contamination or contact with blood, body fluids or contaminated 
equipment” (CDC, 2013, p. 6).  This means that medication should be drawn and labeled 
outside of patient areas, including the operating room.  This is virtually never adhered to, 
and never will be, as long as the anesthesia providers use vials that must be drawn up 
when conditions mandate their administration.  There is an obvious contradiction 
between the current practice standards and the CDC’s guidelines.    
“Operating rooms and the perioperative area are the most medication-intensive 
areas in a hospital.  These areas use more medications, especially high-alert medications, 
than any other unit, but operate with fewer safety measures in place” (Brown, 2014, pp. 
466).  The Anesthesia Patient Safety Foundation’s (APSF) new standard of medication 
administration includes further safety measures that exceed the standard Joint 
Commission recommendations of labeling and visual verification of labels.  “Pre-filled 
syringes and standardization of medications, workstations, and technology have been 
shown to reduce the number of Adverse Drug Events (ADE) by at least 21% and, in 
certain institutions, by much more than 21%.  The available information is sufficient to 
promote the implementation of pre-filled or premixed syringes in anesthesia departments 
to reduce the number of ADEs and become compliant with the APSF, Joint Commission, 
and Institute of Medicine” (Brown, 2014, pp. 465-469). 
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To provide additional evidence for practice, the APSF states that high alert drugs, 
such as phenylephrine and epinephrine, used routinely by anesthesia providers, should be 
available in standardized concentrations and/or diluents prepared by pharmacy in a ready-
to-use syringe and should have standardized, fully compliant, machine readable labels.  
They continue to include that “routine provider-prepared medications should be 
discontinued whenever possible.  Clinical pharmacists should be part of the operating 
room team, and standardized pre-prepared medication kits by case type should be used 
whenever possible” (Eichhorn, 2010). 
 According to the World Health Organization (WHO), applicable legislation is 
defined as the instrument by which the implementation of a drug policy is given a legal 
basis by statutorily defining the various strategies for achieving the objectives of the 
policy.  It also defines the qualifications, duties, privileges, and obligations of 
individuals, organizations, and institutions.  “For the effective implementation of 
legislation, there is a need to review and update the relevant laws regularly, in 
consultation with relevant stakeholders (such as pharmaceutical companies, anesthesia 
providers, and surgical patients), in order to achieve the desired objectives.  Some of the 
existing drug laws are in dire need of review and harmonization” (National Drug Policy, 
2005, p. 14).   
 The wave of the future is pre-filled syringes and pre-filled, pre-labeled syringe 
filled anesthesia drug trays.  The American Association of Nurse Anesthetists’ AANA 
News Bulletin (2015) highlighted pre-filled syringes in anesthesia practice.  They cited 
companies, such as PharMEDium, who pay tribute to their specific pre-filled, pre-labeled 
syringe, which utilize the American Society for Testing and Materials standard for color 
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differentiation of anesthesia syringe medications, endorsed by the American Society of 
Anesthesiologists (p. 36). 
 Differentiating color is a helpful visual differentiating tool but color alone it is not 
enough to distinguish medications within a class, so the medication name was 
implemented in six different locations to guarantee the most crucial information is 
observable from any angle.  They further added specific consistent lettering suggested by 
the Institute for Safe Medication Practices (ISMP), and a variety of visual cues, including 
shapes and reverse print to create a conspicuous layout proposed to support medication 
administration in emergency situations.   After completing a widespread facility 
investigation of existing practice and previous medication errors to improve the OR label 
draft, syringe labels now include drug name on circular rings and vertical stripes 
alongside graduated inscription, guaranteeing the medication name is visible during drug 
selection but also through administration when the principal focal point is on the 
graduated marks (PharMEDium, 2014).  Quality improvements include the 
implementation of sterile, industrially accessible medication in ready-to-use medication 
syringes.   
 The European Board of Anesthesiology (EBA) recommendations for safe 
medication practice state that “all medications need to be prepared for routine use in 
anesthesia, intensive care, and emergency medicine and pre-filled syringes should be 
used wherever possible” (EBA recommendations for Safe Medication Practice, 2011 p.  
294).  Research provided many studies revealing evidence of utilization of pre-filled 
syringes, especially in an article entitled “Medication Errors during preparation and 
treatment delays.”  The objective was to examine medication errors that occurred during 
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the preparation and administration of medication used in an intensive care unit.  The 
analysis was carried out in a 12-bed ICU and data, were composed over 16 randomly 
selected days at various medication times.  A skilled spectator worked alongside the 
nurses during medication rounds.  Errors were recorded during the inspection period of 
medication administration and preparation.  Drugs most used in the ICU were selected.  
Information about the method of preparation and administration of the chosen 
medications were analyzed against a checklist, which was organized using manufacturers' 
instructions.  Out of 524 preparations and administrations, the calculated number of 
opportunities for error was 4040.  Identifiable errors were 380/4040, (9.4%), and of those, 
33.6% were associated to the preparation process and 66.4% with the administration 
process.    
 Clinically relevant outcomes were assessed, and the risk and benefits of the 
treatment were noted, and while it is clear that medication errors would be reduced and 
treatment delays improved, this method would have considerable monetary implications 
for healthcare providers.  Further research is needed in the area of cost effectiveness.  
Lastly, the expectation is safe, effective, first-rate treatment.  “Providing infusions in pre-
filled syringes would reduce medication errors and treatment delays, improve patient 
safety, and effectively meet these expectations” (Fahimi et al.,  2008, p. 104). 
 According to Dr. Stratman, lead researcher from Barnes-Jewish Hospital, “the use 
of pre-filled, pre-labeled syringes likely will be cost neutral to the hospital, with the costs 
of outsourcing medications offset by the savings in otherwise wasted drugs.  But when 
you look at the impact of the initiative on quality and safety for the patients … it’s what’s 
right to do even if it costs a little more” (Blum, 2013, p. 3). 
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 Further incidence of medication errors and treatment delays were directly 
evaluated in a study analyzing errors during the preparation of medication.  The 
background considered the degree and regularity of errors and treatment delays made as a 
result of bedside preparation, instead of using pre-filled syringes.  Forty-eight ICU nurses 
volunteered in this randomized, blinded, controlled study carried out in a metropolitan 
hospital.  Medications were drawn from concentrated vials, or they were provided in pre-
filled syringes beforehand. 
They compared both preparation time and concentration of the medication against 
medication prepared by pharmacists.  It took nurses 156 seconds to initiate infusions 
when using pre-filled syringes compared with 276 seconds when preparing them from 
vials, averaging a delay of 106 seconds.  When using pre-filled syringes, medication 
errors were 17 times less likely and they resulted in a reduction of medication errors and 
treatment delays while simultaneously improving patient safety (Adapa et al.,  2012). 
The pre-labeled syringes saved money and time, and increased patient safety. The 
review supports the need for further study in order to determine each locations specific 
monetary value of medication errors. The results will help providers care for patients as 
patient safety and safe medication administration can directly be applied into clinical 
practice.  Standard medication labels should be available to the provider to improve 
patient safety (Adapa et al.,  2012). 
 In a letter written by a group of notable anesthesia providers, ranging from noted 
authors, CRNAs, and MDAs, there were a list of recommendations and requested 
revisions made to the JCAHO written requirements. They stated that they had exceptional 
concerns with exclusion on pre-labeled syringes, identification of spinal and epidural 
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medication via labeling, and the label authentication requirements when two providers 
are involved.  They gave specific reasons for their requests, and it was clear, based on 
their argument, that changes needed to be made to the JCAHO recommendations and 
requirements.  The overturning of policies and procedures as outlined improves patient 
safety and efficiency of practice (Santoro, Stoelting, Wagner, & Warner, 2010). 
 A study in an OB unit in France examined the use of ephedrine pre-filled syringes 
and concluded, with valid evidence, that they did indeed reduced anesthesia costs.  It 
evaluated the utilization, expense, and consumption of ephedrine against the use of 
ephedrine via pre-filled syringes.  The expense included vials and consumable equipment 
against pre-filled syringes and results were evaluated on the base of cost.  Over one 
hundred parturients were evaluated in the study.  They found that 155 vials were used for 
verses 45 pre-filled syringes.  The outcomes of the study demonstrate that the use of pre-
filled syringes considerably reduced medication waste and decreased cost in OB 
anesthesia.  The results showed that the use of pre-filled syringes significantly reduced 
the wastage of ephedrine, allowing subsequent cost minimization in obstetrical anesthesia 
(Bellefleur et al., 2009).  If it were possible to ensure that the pre-filled syringes were 
used for “immediately for bradycardias… then the pre-filled syringes [would] save 
money” (De Mello & Vipond, 2000 p. 303). 
 In conclusion, The U.S. National Library of Medicine states that in 2008 the annual 
cost of measurable medical errors that harm patients was $17.1 billion and the second 
most common medication error is dilutional drug errors (U.S. National Library of 
Medicine National Institute of Health, 2011).  
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 A new policy in favor of standardization of pre-filled syringes and pre-filled 
anesthesia drug trays would significantly reduce medication waste and decrease cost.  By 
simply changing the policy on the delivery system, and nothing else about a given 
providers practice, cost is decreased, medication waste among anesthesia providers 
becomes significantly decreased, patient safety is enhanced, induction time is decreased, 
and the providers job is more streamlined.   
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CHAPTER II 
METHODOLOGY 
Design and Target Population  
In establishing a comprehensive cost benefit analysis, comparing a sample pre-
filled anesthesia drug tray against a vial-filled drug tray, recommendations, standards, 
and guidelines were compiled to show a shift toward pre-filled, pre-labeled syringes.  In 
2010, JCAHO released updated labeling criteria to be followed in procedural areas.  In an 
effort to comply with The 2010 National Patient Safety Goals, “when a drug is drawn 
into a syringe or otherwise used from its original container it must be immediately 
administered with no intervening steps or functions prior to administration” (The 2010 
National Patient Safety Goals, 2010, p. 5).  They further outline labeling medications and 
solutions in the context of NPSG.03.04.01 which states that “the labeling expectation for 
this safety goal are consistent with the requirements which state that the label must 
include: The drug name, strength, and amount, expiration date when not used within 24 
hours, expiration time if less than 24 hours, which applies to only a few drugs, as well as 
the date prepared and diluent for all compounded IV admixtures”.  In light of these safety 
goals, JCAHO promotes the purchase and use of pre-filled, pre-labeled syringes such as 
on procedure trays (The 2010 National Patient Safety Goals, 2010). 
As previously stated, the CDC Infection Prevention Checklist for Outpatient 
Settings: Minimum Expectations for Safe Care state that “Injections are prepared using 
aseptic technique in a clean area free from contamination or contact with blood, body 
fluids or contaminated equipment” (CDC, 2013, p. 6).  Therefore, medication should be 
drawn and labeled outside of patient areas, including the operating room. 
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According to the AANA (2014), “operating rooms and the perioperative area are 
the most medication-intensive areas in a hospital.  These areas use more medications, 
especially high-alert medications, than any other unit, but operate with fewer safety 
measures in place” (p. 465).  The APSF new model of medication administration includes 
further protection to surpass the JCAHO recommendations of labeling.  “Pre-filled 
syringes and standardization of medications, workstations, and technology have been 
shown to reduce the number of ADEs by at least 21% and, in certain institutions, by 
much more than 21%.  The available information promotes the implementation of pre-
filled syringes in anesthesia departments to reduce the number of ADEs and become 
compliant with the APSF, the Joint Commission, and Institute of Medicine” (Brown, 
2014, pp. 465-469).   
Detailed Procedures 
In an effort to meet the various recommendations and guidelines, an initial 
baseline was established to include a set of specific medications, with specific dilutions, 
labels, and quantity of each.  A list of 37 anesthesia drugs, used by various facilities 
throughout Mississippi, was formulated.  Next, a comprehensive analysis compared the 
current vial-filled medication administration of a regional medical center in south 
Mississippi against pre-filled syringes.  The specific dilution of each medication, the 
concentration of each vial, and the cost of each medication were identified. Specific 
variables were compared to offer the most cost-effective option for this specific facility.  
Specific information gathered included a description of the most frequently used 
medications, vial cost, cost of preparation and supplies such as blunt needles and empty 
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syringes, and monthly volume of specific medication administration (See Appendices A 
and B).   
Setting and Evaluation  
Once this information was compiled at a facility in south Mississippi, 
recommendations were made to change only what would benefit the facility.  For 
example, if a particular medication was rarely used or if the pre-filled medication might 
expire before the providers thought they would be able to administer the syringe, that 
syringe was not recommended for change from vial to syringe.  The analysis included all 
commonly administered anesthetic medication against pre-filled syringe availability, cost, 
and expiration.  A list of medications was compiled in a cost benefit analysis and a 
medication tray provided to ensure that medications were always in the same location to 
ensure safety and to streamline delivery.  For example, the provider knows, almost 
without having to think about it, that the Rocuronium is always located in the top right 
corner, red in color, in a 5ml syringe at a dilution of 10 mg/ml.  This way, no matter 
which OR the provider practices in, the medication is the same every time.  The direct 
cost was compared between each vial and the counterpart syringe.  Final calculations 
were made and revealed significant decrease in cost of both individual pre-filled syringes 
and the finalized anesthesia drug tray.  These findings, however, represented only the 
direct cost.  Further substantial financial savings were identified to include indirect cost 
benefit of pre-filled syringes.  Lastly, providers were interviewed to discuss the positive 
and negative aspects of pre-filled syringes, and potential room for improvement.  
Feedback was then taken from the providers, and all of the paralytics were changed to 
vary in color instead of all being red in color, following the recommendations of the 
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providers.  This was the only notable recommendation from the providers.  These data 
were utilized in the results section for the Business Plan. 
Table 1 
The Essentials of Doctoral Education for Advanced Nursing Practice 
 
DNP 
Essential  
Fulfillment of DNP Essential 
 
I The specific scientific underpinnings for practice: 
 
The benefits to the practice of anesthesia are evident in the direct and 
indirect cost benefit analysis.  The research shows that pre-filled 
syringes increase safety, decrease medication waste, and is more cost-
effective than vials.  Furthermore, regulations and recommendations of 
governing bodies encourage automated dispensing systems and pre-
filled syringes in the future. 
 
II Organizational and systems leadership for quality improvement and 
systems thinking: 
 
Quality improvement measures were utilized in multiple research 
articles, and prove that pre-filled syringes, when implemented, 
improve quality and safety while decreasing the cost of healthcare by 
significantly decreasing drug waste and dilutional medication errors. 
 
III Clinical scholarship and analytical methods for evidence-based 
Practice: 
 
Despite the need for further quantifiable research, the implications of 
existing 17.1 billion dollar medication errors were used to show 
obvious results of the analysis.   
 
IV Information Systems/Technology:  
 
Patient Care Technology for the cost benefit analysis shows that by 
simply changing nothing more than the packaging technology used to 
deliver medication multiple systems are significantly improved.  
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Table 1 (continued). 
 
DNP 
Essential  
Implications for Pre-filled syringes 
 
V Improvement and Transformation of Health Care:   
 
The implementation of pre-filled syringes offer the promise of 
transforming and improving health care via improved quality and 
safety and decreased cost of healthcare in the areas of significant 
decrease of drug waste and dilutional medication errors. 
 
VI Health Care Policy for Advocacy in Health Care:   
 
Evidence showing pre-filled syringes’ ability to improve healthcare 
provides the foundation for unassailable advocacy for improved 
outcomes, which should be the basis of health care policy   
 
VII Interprofessional Collaboration for Improving Patient and Population 
Health Outcomes:   
 
In order to successfully coordinate a comprehensive cost benefit 
analysis to improve outcomes, interprofessional collaboration is 
essential 
 
VIII Clinical Prevention and Population Health for Improving the Nation’s 
Health:   
 
Pre-filled syringe implementation dramatically drive the cost of the 
nation’s health care down and clearly prevent costly medication errors 
while simultaneously improving ease of practice for anesthesia 
providers 
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CHAPTER III 
RESULTS 
Reliance Pharmaceuticals & Consulting Business Plan  
 Based on the research that shows the superiority of pre-filled syringes, reliance 
Pharmaceuticals was created to bridge the gap between the research and clinical practice. 
Reliance Pharmaceuticals is a company that manufactures customizable pre-packaged 
drug trays or other drug delivery systems and consults for drug delivery systems.  We 
have a compounding pharmacy under contract to draw up and pre-package syringes, 
specifically organized for anesthesia providers’ unique needs based on their drug usage, 
setup, and dispensing system.   
Mission 
 Our Mission is to provide superior products for superior outcomes. We aim to make 
available superior pharmaceutical products with improved value to anesthesia providers 
and other users, advancing patient care and improving the quality of anesthesia and 
healthcare.  Our goal is to be the nation’s largest privately held and one of the fastest 
growing distributors of pre-filled syringes in the United States.  Our focus is serving 
hospitals, surgery centers, physician offices and other health care markets.   
Objectives 
 Our objectives are to be fully founded by October 2015, reach 7 contracts locally, 
followed by a spread of contracts in the state of Mississippi, followed by contracts 
regionally, and ultimately nationally.  Customer satisfaction is at the cornerstone of our 
business and is measured by anesthesia surveys, return customers, and increased sales.   
We endeavor to guide our profession with the most cost-effective medication and 
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invaluable clinical solutions for anesthesia providers and their patients, while advancing 
superiority and efficacy in each part of our process. 
 This is a growing industry, starting locally and working toward national 
distribution.  Short-term goals include moving from vial-filled trays to pre-filled syringe 
trays, while long-term goals are standardization of pre-filled syringe drug trays within the 
operating room.  Such standardization will thus augment our sales.  Strengths include 
providing an opportunity to increase operating room turnover rates and decrease 
medication related errors and infections, and decrease drug administration delays.  
Recommendations from the CDC and Joint Commission further strengthen our overall 
goal toward safer, more streamlined practice.  Once implemented, hospitals and 
anesthesia providers will see the benefit of pre-filled syringes first hand.  As anesthesia 
providers ourselves, we have experienced the lag time of having to gather and prepare 
medications between cases.  We bring this experience and understand the urgency in 
emergency situations.   
 Our goal is to become a Limited Liability Corporation.  We have selected this form 
because we blend elements of partnership and corporate structures.  Partnerships are 
between compounding companies and anesthesia providers.  We blend the corporate 
structure of CEO, CFO, VP of sales and marketing, and VP of public relations with the 
partnerships between compounding pharmacies and anesthesia provider. 
Guidelines, Standards, and Recommendations 
In 2010, the JCAHO released updated labeling criteria to be followed in 
procedural areas.  In an effort to comply with The 2010 National Patient Safety Goals, 
“when a drug is drawn into a syringe or otherwise used from its original container it must 
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be immediately administered with no intervening steps or functions prior to 
administration” (The 2010 National Patient Safety Goals, 2010, p. 5).  They further 
outline labeling medications and solutions in the context of NPSG.03.04.01 which state 
that “the labeling expectation for this safety goal are consistent with the requirements 
which state that the label must include: The drug name, strength, and amount, expiration 
date when not used within 24 hours, expiration time if less than 24 hours (which applies 
to only a few drugs), as well as the date prepared and diluent for all compounded IV 
admixtures”.  In light of these safety goals, the JCAHO approves the purchase and use of 
pre-filled, pre-labeled syringes such as on procedure trays.  (The 2010 National Patient 
Safety Goals, 2010). 
The CDC Infection Prevention Checklist for Outpatient Settings: Minimum 
Expectations for Safe Care state that “Injections are prepared using aseptic technique in a 
clean area free from contamination or contact with blood, body fluids or contaminated 
equipment” (CDC, 2013, p. 6).  This means that medication should be drawn and labeled 
outside of patient areas, which would include the operating room. 
According to the AANA (2014), “Operating rooms and the perioperative area are 
the most medication-intensive areas in a hospital.  These areas use more medications, 
especially high-alert medications, than any other unit, but operate with fewer safety 
measures in place” (p. 465). APSF new model of medication administration includes 
further protection to surpass the regular JCAHO recommendations of labeling.  “Pre-
filled syringes and standardization of medications, workstations, and technology have 
been shown to reduce the number of Adverse Drug Events (ADE) by at least 21% and, in 
certain institutions, by much more than 21%.  The available information is sufficient to 
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promote the implementation of pre-filled or premixed syringes in anesthesia departments 
to reduce the number of ADEs and become compliant with the APSF, Joint Commission, 
and Institute of Medicine” (Brown, 2014, pp. 465-469).   
High alert drugs, such as phenylephrine and epinephrine, should be available in 
standardized concentrations/diluents prepared by pharmacy in a ready-to-use (bolus or 
infusion) form and ready-to-use syringes and infusions should have standardized fully 
compliant machine– readable labels. Furthermore, “Routine provider-prepared 
medications should be discontinued whenever possible.  Clinical pharmacists should be 
part of the perioperative/operating room team, and standardized pre-prepared medication 
kits by case type should be used whenever possible” (Eichhorn, 2010, p. 25). 
Products and Services 
 Our product involves a consolidation of commonly used, and some uncommonly 
used, medications in shrink-wrapped, pre-filled syringes in a cut-foam insert within a 
plastic tray and/or pre-filled syringes in automated delivery systems such as Pyxis or 
Omnicell.  We will have our syringes pre-filled and prepared at our contracted 
compounding pharmacy that will guarantee the expiration dates and the highest quality 
compounding and sterilely in our prepared syringes.  Per the CDC and JCAHO 
guidelines, our trays will have pre-filled and pre-labeled syringes that bypass human error 
and improve safety and efficacy of the anesthetic process and thus significantly decrease 
medication errors, drug waste, and response time during emergency situations, while 
increasing room turnover rates, and continuity of care.   
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Reliance Pharmaceuticals four key areas of Service 
1. Assessment: 
Reliance Pharmaceuticals’ dedicated operating room specialists are trained to help assess 
your individual needs.  Each consultation will include a confidential detailed observation 
report to help you evaluate drug usage and waste.  Evaluations of medication usage are 
utilized to support implementation of pre-filled syringes based on the hospital’s goals for 
improving medication safety and process efficiencies.  The assessment ensures an 
improved compliance among The JCAHO as it pertains to labeling and USP 797. 
2. Development: 
The Reliance operating room specialist will include input from both pharmacy and 
anesthesia to develop custom medication tray layouts to support a comprehensive 
solution. 
3. Maintenance: 
The Reliance operating room specialist will provide ongoing support to ensure optimal 
integration. 
4. Implementation: 
Reliance specialists will assist with every step of the implementation process to support a 
smooth safe and efficient process.  A detailed implementation timeline is provided to help 
ensure a seamless transition to Reliance ready-to-use services. 
Benefits: 
1.  Seamless Integration: 
The dedicated Reliance operating room specialist will provide you with a customized 
solution that meets pharmacy and anesthesia requirements.   
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They will assist you through every step of the process to ensure a smooth transition to 
ready-to-use medications. 
2. Compatible Storage Solutions: 
Reliance’s ready-to-use syringes are compatible with medication trays designed for 
anesthesia carts, as well as the most commonly used automated dispensing cabinets, 
including mini-drawers for controlled substances. 
2. Evaluation:  
The confidential consultation will help identify opportunities to reduce drug waste and 
determine which Reliance preparations offer the best overall value for your needs. 
3. Standardized Drug Tray Design: 
Medication trays in various colors can be used to further differentiate the specialty trays 
from the general surgery trays. 
Marketing Plan and Economics 
 In order to succeed, effective marketing and branding are essential.  This begins 
with vigilant, methodical investigation.  It is precarious to take for granted that our 
company already knows about our anticipated market.  Significant market research was 
gathered and primary as well as secondary marketing research was utilized.  Data 
collection were procured from the Cochrane Library, CINAHL, MEDLINE, governing 
anesthesia entities, professional associations and professional publications provided 
industry-specific data, and local hospital demographics were critical in defining the local 
market.  Specific methodologies outlined comparison between current trends and 
proposed changes.  Information was packaged for presentation to key stakeholders and 
decision makers at each given facility. 
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Our initial market consists of seven locations within the greater Hattiesburg area 
including Forrest General Hospital, Larry A. Woodall, Orthopedic Institute, Southern 
Bone and Joint, Wesley Medical Center, Hattiesburg Eye Clinic, and Southern 
Anesthesia.  In addition to the initial seven facilities, five other facilities will provide 
opportunity for growth including ambulatory surgery centers, plastic surgery centers, 
Hattiesburg GI associates, and Southern Eye Center. 
Table 2 
Variable Shipping Costs 
 
Facility Variable number of drug trays used daily 
 
Forrest General Hospital 50 
Larry A.  Woodall 25 
Orthopedic Institute  25 
Southern Bone and Joint 25 
Wesley Medical Center 50 
Hattiesburg Eye Clinic 25 
Southern Anesthesia 50 
 
Reliance Variable Profit: 205 Trays (daily):  Cost and Profit breakdown: $0.50 per medication, $5-15 dollars per tray, average 205 
cases daily for all accounts equals $2,050 daily, multiplied x 7 days a week is $14,350 per week, multiplied x 52 weeks in a year = 
$746,200 annually.  A $0.05 discount per syringe to Reliance is negotiated from contracting compounding pharmacy.  (NOTE: not all 
drugs from every tray will be used for any given case, therefore Reliance profit is variable depending on any given surgical case) 
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Reliance has 7 out of 11 facilities offering surgical services within the greater 
Hattiesburg area.  This yields a 58% market share.  Prior to standardization of pre-filled 
syringes (our long term goal), there is an undetermined demand, however, our goal is to 
create a high demand where there is none now.  Current trend is vial use from pre-
packaged anesthesia drug trays in which the provider prepares each medication 
individually as needed.  Unfortunately this, more often than not, is done is such a way to 
violate the guidelines and recommendations set by the governing entities.  Pre-filled 
syringes are used in O.B suites and trauma suites but there are no pre-packaged drug trays 
with pre-filled syringes at these locations currently.  Our goal is to secure local facility 
contracts and then grow statewide, regionally, nationally, and eventually standardize pre-
filled syringes, where we will already have the majority of the market share.  Potential 
barriers include contract negotiations, future competition, and adequate patenting.   
Table 3 
Capital costs and Startup expenses 
 
Factor Monthly Cost 
 
Furnished Office building deposit $2000 
Utilities deposit (electric, sewage, internet, water, phone) $500 
Webpage setup $500 
Travel Expenses $2,795(gas), $400 (food)  $3195 
Rent $1000 
Attorney fee (annually) / contracts, etc. $250/hr x 2 hrs each x 6 
occasions: $1500 + LLC (annually) $800 = $2300 
$192 
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Table 3 (continued). 
 
Factor Monthly Cost 
 
CPA (Monthly)  $500 
Webpage maintenance $200  
Patent on pre-filled drug tray (one-time fee) $500 - $10,000  
 
  To avoid potential financial barriers, high costs of both drugs and shipping will be 
transferred to the hospital or surgery center, who can then transfer the cost to each patient 
once drugs are used (Reliance system helps ensure that all charges are captured to 
facilitate this transfer.) Specific cost analysis is outlined (Appendix A).  To address 
potential barriers associated with patenting our product, wholesale prices are negotiated 
and order in bulk to reduce cost to the healthcare facility.  This would prevent the 
provider from ordering directly from our wholesaler.  If the government standardizes pre-
filled syringes, a monopoly would exist on anesthesia drug trays in our local market.  If 
the economy suffers, hospitals might be prone to cut costs, including seeking out the 
cheapest (not necessarily the best or safest) drug options.  Hopefully, standards, 
guidelines, and recommendations will bring about standardization and such change will 
bring about pre-filled syringe standardization.   
Contracts are to be extended three to six months based upon the need of each 
individual facility.  Warranty, refund, and quality responsibility are transferred to the 
manufacturer/compound pharmacy who guarantees the quality of their dilution, labeling, 
measurement, life expectancy and sterility.  Shipment will be handled directly by the 
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compounding pharmacy.  Our initial market consists of 7 locations within the greater 
Hattiesburg area including Forrest General Hospital, Larry A. Woodall, Orthopedic 
Institute, Southern Bone and Joint, Wesley Medical Center, Hattiesburg Eye Clinic, and 
Southern Anesthesia.   
Our competition would be drug tray distribution companies who distribute filled 
vials instead of filled syringes.  Other competition would be drug dispensing system 
companies such as Pyxis and Omnicel.   
They will be competitive in cost and they also have the market now.  Our biggest 
challenge will be getting the decision makers to choose our drug trays. 
Table 4 
Competitive Analysis Table  
 
Factor Reliance Strengths Weaknesses Competitor A Competitor B 
 
Products Superior Compliant 
Safety, $, 
Labels, 
Dilution, 
Speed 
Expensive Vials Pre-labed, 
Pre-filled, 
Pre-packaged 
Price Variable  Saves $ - 
med errors 
/ turn-over 
time  
More 
expensive 
initially  
Variable Variable  
Quality Superior Same as 
less 
effective 
competitor 
N/A N/A N/A 
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Table 4 (continued). 
 
Factor Reliance Strengths Weaknesses Competitor A Competitor B 
 
Appearance Pre-filled 
immediate
ly 
available 
Immediate 
available  
N/A Familiar vials  Pre-filled 
immediately 
available  
Sales 
Method 
Direct 
B2B sales 
Personal  Potential 
loss of 
business  
Equal  Equal  
Advertising Direct 
B2B  
Personal / 
Reliable  
Less 
popular  
Nation Wide 
commercials  
Trusted, 
reliable, 
familiar  
Image  Equal  Equal, 
Compliant 
N/A Vials – 
familiar  
Equal  
Selection Equal Equal Equal Equal Equal 
Stability Equal as 
long as 
they used 
the vial 
correctly 
Equal Equal Equal Equal 
Expertise Equal Equal Equal Equal Equal 
Reputation  Weakness, 
must 
establish a 
reputation 
New and 
Evidence 
Based  
New and 
unknown  
Known, 
respected, 
trusted 
Bright Future 
(EBP) 
 
Our niche corner of the market is a pre-filled, pre-labeled, pre-packaged 
anesthesia drug tray.  Pre-filled pre-labeled syringes cut down on costly medication 
errors, decreased contamination, due to their being drawn under a sterility hood, 
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decreased draw-up time, and decreased room turnover time.  This enables us to have the 
market share of competition in our targeted area with the ability to expand statewide, 
regionally and nationally with ultimate standardization of our product, which will give us 
a monopoly on the market.  Our marketing strategy will be targeted, marketed, scheduled 
presentations at local facilities.   
  
 
 
 
 
 
 
 
Figure 1. Business Card Design with bright blue and black color scheme to augment the 
operational plan and promotion  
 
All syringes will be pre-packaged via contracted compounding pharmacy.  
Quality is guaranteed via individual compounding pharmacy that prepare the syringes 
under sterile, hooded conditions.  Customer service will include and ensure that each 
facility has adequate supply, ability to replace damaged syringes, and an open line of 
communication for questions/comments and restock requests.  Monthly and weekly 
medication usage statistics for each drug will be requested from each facility and will be 
 
RELIANCE  
PHARMACEUTICALS 
105 MARSHALL PLACE HATTIESBURG, MS. 39402 
RELIANCE.PHARMACEUTICALS@GMAIL.COM 
 
 
 
(601)-480-7978 LANCE KENNEDY 
CEO 
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coupled with specific short-term inventory requests.  The amount of space needed will be 
minimal.  Trays will be completed per order due to expiration constraints.  No building 
will be needed for medication tray storage, as they will be shipped directly from 
compounder to facility.  Business hours will be Monday through Friday from 8am to 5pm 
with 1 person on call 24 hours a day, 7 days a week including holidays, should an 
emergency surface.   
Permit to dispense and distribute medications.  This is placed in the hands of the 
compounding pharmacy.  Medication control, dispensing and distributing are regulated 
and records of each medication and amount must be recorded and filed.  Liability 
insurance will include $6000/year per million dollars of coverage.  Trademarks 
associated with completed anesthesia trays are still pending.  Medical professionals, 
specifically CRNAs, will be employed upon expansion.  As the business grows, 
employees will be interviewed with a minimum requirement being a CRNA with 
adequate business experience.  Original employees (4) will negotiate an equal salary pay 
rate with additional payment for call schedule and overtime.  On-the-job training will be 
needed for new hires after a day of classroom time to cover basic protocol, substance 
abuse training, and specific job requirements.   
The beginning schedule will be all employees 8am-5pm Monday through Friday 
with an on-call rotation including but not limited to:  professional communication with 
compounding pharmacy and health care facility, mediate sales and consulting and acquire 
new business, process medication orders, must function in strict accordance with 
standard, written procedures and guidelines with deviation approved by owner.   
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       Seasonal buildups are negligible since orders will be processed and produced 
upon order request, and medications expire and lead-time will depend on the supply in 
need and the current order load.  Processing can be sent to an outlying compounding 
pharmacy if the current pharmacy load is exceeded.   Multiple compounding pharmacies 
are contracted to avoid drug shortages and existing customers get priority in the event of 
such drug shortages.  Inventory furnished will be split evenly between compounding 
pharmacies. 
   Contracted Compounding Pharmacies include Advantage Compounders located at 
6375 U.S. Highway 98 West Suite 40 & 50 Hattiesburg, MS 39402 and Vital Care 
Compounders located at 115 South 40th Avenue Hattiesburg, MS 39402.  Delivery will 
be arranged by our company to pick up the product and deliver it directly to the health 
care facility.  Sale is complete upon full payment of each order.  Reliance 
Pharmaceuticals retains their $0.50 per drug and remaining payment goes directly to 
compounding pharmacy for order preparation.  Credit will be used only if absolutely 
necessary and must be approved by the owner.  The creditworthiness of the healthcare 
facilities will be determined by history of sales to that particular facility and remain at the 
owners discretion.  New accounts mandate initial full payment and where future credit 
options are allowed, payment will be due within 30 days of product delivery. If late 
payment is expected, a phone call is to be made within 30 days.  A letter will be sent 
when 7 days past due and at 30 days past due, attorneys will begin issuing letters.   
Management and Organization 
The three initial partners and investors will be responsible for managing specified 
daily business as agreed upon via owner and final decisions are to filter through owner.   
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As Certified Registered Nurse Anesthetists, each partner will bring to the business an 
understanding of the drugs used, clinical experience of how efficient and effective our 
product is, and how well it will benefit the facility that purchases.  In the event of conflict 
among partners, owner retains final and ultimate authority.  No loans will be applied for, 
as initial startup costs are invested via owner and three partners/investors.   
Table 5 
Professional Advisory and Support 
 
Service   Name 
 
Owner Lance Kennedy 
Board of Directors  Lance Kennedy, Sayha Ma, Chris Turner, 
Jarrod Fontenelle 
Management Advisory Board Patsy Anderson, Vicky Stuart, Bonnie 
Harbaugh 
Attorney Jack Denton Law office PLLC 
Accountant James McDonnell, CPA 
Insurance agent  Lance Ware (State Farm) 
Banker  Wells Fargo 
Consultants, Mentors, and key advisors  Board of Directors and Advisory Board 
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CHAPTER IV 
SUMMARY 
The future of Anesthesia drug delivery is obvious, and, the data provide clearly 
defined recommendations and guidelines.  The research reveals overwhelming evidence 
that the use pre-filled syringes would reduce medication errors and treatment delays and 
improves patient safety outcomes (Fahimi et al., 2008).  “When you look at the impact of 
Pre-filled syringes and their impact on quality and safety for the patients, it’s what’s right 
to do even if it costs a little more” (Blum, 2013, p. 3).  Also, when using pre-filled 
syringes, medication errors are 17 times less likely and would reduce medication errors 
and treatment delays, and improve patient safety (Adapa et al., 2012).  Pre-filled syringes 
reduce significantly the wastage of medication, allowing subsequent cost minimization in 
anesthesia (Bellefleur et al., 2009).   
Summary of Findings 
The U.S. National Library of Medicine states that in 2008, the annual cost of 
measurable medical errors that harm patients was $17.1 billion, and the second most 
common medication error was dilutional drug errors (U.S. National library of Medicine 
National Institute of Health, 2011).  Additionally, the implementation of pre-filled 
syringes stands to decrease the cost of healthcare by $420,000,000 annually just from the 
21% decrease in Adverse Drug Events (Brown, 2014, pp. 465-469).   If it were possible 
to ensure that the pre-filled syringes were used, then the pre-filled syringes [would] save 
money (De Mello & Vipond, 2002, p. 303).  
To reiterate, the 2010 National Patient Safety Goals state that “when a drug is 
drawn into a syringe or otherwise used from its original container it must be immediately 
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administered with no intervening steps or functions prior to administration” (The 2010 
National Patient Safety Goals, 2010, p. 5).  This makes pre-filled syringes an obvious 
choice.   As well, the CDC’s minimum expectations for safe care are that injections are 
prepared outside of patient areas, which would include the operating room and as such, 
pre-filled syringes are, again, the obvious solution (CDC, 2013).  Furthermore, according 
to the AANA (2014), “the available information is sufficient to promote the 
implementation of pre-filled or premixed syringes in anesthesia departments to reduce the 
number of adverse drug events and become compliant with the Joint Commission, and 
Institute of Medicine”  (Brown, 2014, pp. 465-469).  It seems to be only a matter of time 
before each individual operating room will be required to have its own automated drug 
dispensing system or pre-filled drug tray.   
 Current policies on Drug storage simply mandate that an entity reasonably show 
that they are adhering to vague medication storage standards.  Anesthesia drug policy, 
storage, and distribution are decided on by each individual facility with minimal attention 
to detail.  If current healthcare policy would ensure the use of pre-filled syringes, their 
standardization would immediately begin to improve outcomes and healthcare cost would 
be immediately decreased. 
 In the OR, precision and split second decisions are essential to the quality of 
patient care.  Instead of relying on vague policy options to steer the quality of anesthesia, 
policy should be created where pre-filled syringes are utilized with pharmacy prepared 
labels that are intended to augment medication name identification during potentially 
grave circumstances.  Further recommendation values policies that included standardized 
color differentiation, easy to read labels with graduated markings, dilution, and expiration 
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dates that would increase quality, speed and efficiency, and dramatically reduce drug 
waste.   
Implications for Nursing Practice  
Reliance Pharmaceuticals specializes in pre-filled, pre-labeled, and prepackaged 
syringes and consulting.  They show how to save the contracting facility approximately 
one million dollars per year and how to significantly decrease dilutional drug errors, drug 
wastage, and ADEs from an anesthetic point of view.  Let’s take a look at how we do 
this.  Dilutional errors are the second most costly medication errors.  Although this may 
be true, there is room for improvement.  The national average of these errors are $21 
billion dollars per year.  Mississippi’s average of medication errors is $420 million 
dollars.  The estimated per hospital medication errors equal $3.5 million dollars.  Twenty-
three percent of dilutional errors come to the average of $805,000 dollars.  In addition to 
dilutional errors, average drug wastes for the surrounding hospitals are $42,000 a year.  
The total savings for increased room turnover, based on research is: 1.85 minutes per 
case.  The average case count in a day of the projected initial hospital contract caseload is 
53 cases a day.  In an effort to use conservative, realistic numbers if 50 cases a day times 
1.5 minutes = 75 minutes a day, 75 minutes times 7 days a week = 525 minutes. 525 
minutes times 52 weeks in a year = 27,300 minutes = 455 hours 11.375 work weeks you 
will get about three months back which equals up to $70/hour x 455 hours = $31,850. 
The cost of an anesthesia tray of vials is $313 dollars.  The time to administer a 
pre-filled syringed drug is 13 seconds, whereas it takes 35 seconds to administer a vial 
drug.  How much money is our business making? Initially, $0.50 per medication, $5-15 
dollars per tray, average 205 cases daily for all accounts, $2,050 daily x 7 days a week 
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$14,350 per week x 52 weeks in a year = $746,200 annually.  Our compounding 
pharmacy pitch: 205 cases daily x seven days a week = 1,435 cases a week x 52 weeks in 
a year = 74,620 cases a year (less unused, redistributed medications).  $13,431,600 per 
year is paid to the compounding pharmacy. 
Conclusion 
The dynamic practice of anesthesia necessitates relentless assessment to generate 
safeguards.  While modification is not always essential, evaluating an organization and 
looking for cost-effectiveness and improved patient care measures can be advantageous 
in treatment of illness, in the facility, and in the entire profession of anesthesia.  
Standardization provides consistency and a universal system, which improves patient 
safety and can lead to departmental cost savings.  In the mission to continually improve 
our practice and patient care during anesthesia, let us hold diligently to the guiding 
principles that catapulted our profession to where it is today.  This continued approach 
should lead us to a standardization of pre-filled, pre-labeled syringes in prepackaged drug 
trays customized to the individual needs of a given facility.  The ability to put aside 
selfish ambition and strive for the greater good will highlight the principles of delaying 
gratification, character, integrity, and dedication to success that has bought and will 
continue to bring out the very best in us, as anesthesia providers, and in healthcare 
throughout the nation.  
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APPENDIX A 
MEDICATION EVALUATION TABLE 
 
Description Vial 
Cost 
Preparation 
Supplies 
Total 
Preparation 
Cost 
Current 
Monthly 
Volume 
Current 
Monthly 
Cost 
Estimated 
Monthly Usage 
post Syringe 
Implementation 
Pre-filled 
Syringe 
Price 
Monthly 
cost for 
Pre-filled 
Syringe 
Financial 
Difference 
 
 
Phenylephrine $4.50 $0.50 $5.00 66 $330.00 40 $4.81 $192.40 -$137.60 
Ephedrine $10.19 $0.50 $10.69 76 $812.44 46 $12.78 $587.88 -$224.56 
Vecuronium $5.45 $0.50 $5.95 54 $321.30 69 $14.99 $1,034.31 $713.01 
Cisatracurium $13.76 $0.50 $14.26 61 $869.86   $0.00 -$869.86 
Rocuronium $8.19 $0.50 $8.69 51 $443.19 31 $8.62 $267.22 -$175.97 
Neostigmine $89.18 $0.50 $89.68 73 $6,546.64 44 $11.30 $497.20 -$6,049.44 
Glycopyrrolate $25.87 $0.50 $26.37 92 $2,426.04 55 $30.81 $1,694.55 -$731.49 
Lidocaine $1.28 $0.50 $1.78 704 $1,253.12 422 $3.83 $1,616.26 $363.14 
Epinephrine $1.18 $0.50 $1.68 13 $21.84 8 $5.38 $43.04 $21.20 
Midazolam $1.37 $0.50 $1.87 186 $347.82 186 $4.52 $840.72 $492.90 
Impact                                    Total monthly impact -$6,598.67 
Annual Impact       ANNUAL Impact -$79,184.04 
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APPENDIX B 
 
PHARMEDIUM SAMPLE LABELING TABLE 
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APPENDIX C 
 
THE UNIVERSITY OF SOUTHERN MISSISSIPPI IRB APPROVAL 
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APPENDIX D 
 
PROJECT TIMELINE 
 
 
Month Activities 
 
May 2013 Complete AANA wellness modules  
August 2013 Complete Collaborative Institutional Training 
Initiative (CITI) 
September 2014 Submit graduate committee chair and member names 
(3) to NAP 
April 2015 Submit Institutional Research Board (IRB) application 
for process approval  
July 2015 Application submitted for Degree and Plan of Study 
July 2015 Submit Contact Graduate Reader form to the Reviewer 
of Graduate Nursing Capstone Projects  
July 2015 Defense of Proposal and submission of approval form. 
Submission of title page  
August – September 2015 Data Collection  
September 2015 Capstone paper corrections. 
Rework data interpretation 
October 2015 Final presentation/Capstone defense. 
 
October 2015 Submit copy of capstone project to Graduate Reader 
for proofing and approval 
December 2015 Graduate  
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